[go: up one dir, main page]

IL160272A0 - Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist - Google Patents

Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist

Info

Publication number
IL160272A0
IL160272A0 IL16027202A IL16027202A IL160272A0 IL 160272 A0 IL160272 A0 IL 160272A0 IL 16027202 A IL16027202 A IL 16027202A IL 16027202 A IL16027202 A IL 16027202A IL 160272 A0 IL160272 A0 IL 160272A0
Authority
IL
Israel
Prior art keywords
pde3
pde4
inhibitor
pharmaceutical compositions
leukotriene receptor
Prior art date
Application number
IL16027202A
Other languages
English (en)
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of IL160272A0 publication Critical patent/IL160272A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16027202A 2001-09-19 2002-09-17 Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist IL160272A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000474 2001-09-19
PCT/EP2002/010423 WO2003024488A2 (en) 2001-09-19 2002-09-17 Combination of a pde inhibitor and a leukotriene receptor antagonist

Publications (1)

Publication Number Publication Date
IL160272A0 true IL160272A0 (en) 2004-07-25

Family

ID=8176066

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16027202A IL160272A0 (en) 2001-09-19 2002-09-17 Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist
IL160272A IL160272A (en) 2001-09-19 2004-02-08 Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160272A IL160272A (en) 2001-09-19 2004-02-08 Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist

Country Status (25)

Country Link
US (1) US20050014762A1 (es)
EP (1) EP1429843B1 (es)
JP (1) JP2005505570A (es)
KR (1) KR20040044946A (es)
CN (1) CN100346831C (es)
AT (1) ATE349243T1 (es)
BR (1) BR0212582A (es)
CA (1) CA2460442A1 (es)
CO (1) CO5560584A2 (es)
CY (1) CY1106365T1 (es)
DE (1) DE60217139T2 (es)
DK (1) DK1429843T3 (es)
EA (1) EA007736B1 (es)
ES (1) ES2279004T3 (es)
HU (1) HUP0500078A3 (es)
IL (2) IL160272A0 (es)
MA (1) MA27136A1 (es)
MX (1) MXPA04002560A (es)
NO (1) NO331885B1 (es)
NZ (1) NZ532279A (es)
PL (1) PL205927B1 (es)
PT (1) PT1429843E (es)
SI (1) SI1429843T1 (es)
WO (1) WO2003024488A2 (es)
ZA (1) ZA200402653B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719518D0 (en) * 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
US20100210611A1 (en) * 2007-10-25 2010-08-19 Roch Thibert Combination therapy
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
SG11201505878UA (en) 2013-02-19 2015-09-29 Pfizer Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
CA2936332A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
ES2733502T3 (es) 2014-08-06 2019-11-29 Pfizer Compuestos de imidazopiridazina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
AU777012B2 (en) * 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
TR200201880T2 (tr) * 2000-01-31 2002-11-21 Pfizer Products Inc. PDE4 izozimerlerinin seçici önleyicileri olarak faydalı nikotinamit benzobağlı-heterosiklil türevleri
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
WO2001090076A1 (en) * 2000-05-25 2001-11-29 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor

Also Published As

Publication number Publication date
ZA200402653B (en) 2005-02-14
EP1429843B1 (en) 2006-12-27
IL160272A (en) 2008-03-20
ES2279004T3 (es) 2007-08-16
CY1106365T1 (el) 2011-10-12
BR0212582A (pt) 2004-10-13
CA2460442A1 (en) 2003-03-27
NZ532279A (en) 2006-02-24
SI1429843T1 (sl) 2007-06-30
KR20040044946A (ko) 2004-05-31
NO331885B1 (no) 2012-04-30
CN1655846A (zh) 2005-08-17
MA27136A1 (fr) 2005-01-03
HK1066752A1 (en) 2005-04-01
DK1429843T3 (da) 2007-04-30
ATE349243T1 (de) 2007-01-15
US20050014762A1 (en) 2005-01-20
WO2003024488A3 (en) 2003-09-04
PL205927B1 (pl) 2010-06-30
EA200400416A1 (ru) 2004-12-30
PT1429843E (pt) 2007-03-30
CN100346831C (zh) 2007-11-07
DE60217139T2 (de) 2007-10-04
HUP0500078A3 (en) 2010-07-28
CO5560584A2 (es) 2005-09-30
WO2003024488A2 (en) 2003-03-27
EP1429843A2 (en) 2004-06-23
HUP0500078A2 (hu) 2005-04-28
PL367414A1 (en) 2005-02-21
MXPA04002560A (es) 2004-05-31
JP2005505570A (ja) 2005-02-24
EA007736B1 (ru) 2006-12-29
DE60217139D1 (de) 2007-02-08
NO20041595L (no) 2004-06-16

Similar Documents

Publication Publication Date Title
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
GEP20084571B (en) Triazole derivatives as vasopressin antagonists
HUP0302476A3 (en) Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
HUP0401656A3 (en) Mch antagonists for the treatment of obesity and pharmaceutical compositions containing them
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
HUP0105488A2 (en) Monoamine reuptake inhibitors for treatment of cns disorders and pharmaceutical compositions containing the compounds
EP1827468A4 (en) LEUPROLID ACETATE AND ACETYLCHOLINESTERASE INHIBITORS OR NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALZHEIMER DISEASE
HUP0304058A2 (hu) Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
HUP0400349A3 (en) Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them
HUP0204458A3 (en) Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
HUP0104085A3 (en) Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension
WO2002081728A3 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
HUP0302068A3 (en) Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
ID29818A (id) Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
IL168308A (en) Compositions containing roflumilast and formoterol
HUP0401858A3 (en) Gal3 receptor antagonist pyrimidine and indolone-derivatives and their use for preparation of pharmaceutical compositions suitable for the treatment of depression and/or anxiety
HUP0302820A3 (en) Indole derivatives useful for the treatment of cns disorders and pharmaceutical compositions containing them
NO20033634L (no) GLyT-1-inhibitorer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed